Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot104910.32687/0869-866X-2022-30-s1-992-997Научная статьяGENE THERAPY: HISTORY OF DEVELOPMENT AND CURRENT STATE (LITERATURE REVIEW)GrechushkinaN. A.grechushkinana@zdrav.mos.ruResearch Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department1511202230s199299717112022Copyright © 2022,2022The article provides a brief overview of the history of gene therapy from its inception to the present. It describes the main events that characterize the periods of history of the formation of this therapeutic direction in medicine; the basis achievements and problems of each periods. It lists the main gene therapy drugs that licensed at different times listed; innovative gene therapy technologies, which are now use in clinical practice or are still at the stage of approbation. The article is a review of publications from the Scopus and PubMed and official information from public Internet sources.gene therapyliterary reviewhistory of gene therapy developmentgene therapy drugsinnovative medicineгенная терапияобзор литературыистория развития генной терапиигенотерапевтические препаратыинновационная медицина[Szybalska E. H., Szybalski W. Genetics of human cess line. IV. DNA-mediated heritable transformation of a biochemical trait // Proc. Natl. Acad. Sci USA. 1962. Vol. 48: P. 2026-2034.][Goswami R., Subramanian G., Silayeva L. et al. Gene therapy leaves a vicious cycle // Front. Oncol. 2019. Vol. 9. Р. 297. DOI: 10.3389/fonc.2019.00297][Безбородова О. А., Немцова Е. Р., Якубовская Р. И. Генная терапия - новое направление в медицине // Онкология. 2016. № 2. С. 64-72.][Rosenberg S. A., Aebersold P., Cornetta K. et al. Gene transfer into humans-immunotherapy of patientswith advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral genetransduction // N. Engl. J. Med. 1990. Vol. 323. P. 570-578. DOI: 10.1056/NEJM199008303230904][Flotte T. R. Gene therapy: The first two decades and the current state-of-the-art //j. Cell. Physiol. 2007. Vol. 213. P. 301-305. DOI: 10.1002/jcp.21173][Keeler C. E. Gene therapy //j. Hered. 1947. Vol. 38. P. 294-298.][Zhou W., Wang X. Human gene therapy: a scientometric analysis // Biomed. Pharmacother. 2021. Vol. 138. Р. 111510. DOI: 10.1016/j.biopha.2021.111510][The First Human Gene Therapy; 2018. URL: https://www.biomol.com/resources/biomol-blog/the-first-human-gene-therapy (дата обращения: 25.05.2022).][Ma C.-С., Wang Z.-L., Xu T. et al. The approved gene therapy drugs worldwide: from 1998 to 2019 // Biotechnol. Adv. 2020. Vol. 40. Р. 107502. DOI: 10.1016/j.biotechadv.2019.107502][Hauswirth W., Aleman T. S., Kaushal S. et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial // Hum. Gene Ther. 2008. Vol. 19. P. 979-990. DOI: 10.1089/hum.2008.107][Maguire A. M., Simonelli F., Pierce E. A. et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis // N. Engl. J. Med. 2008. Vol. 358. P. 2240-2248. DOI: 10.1056/NEJMoa0802315][Aiuti A., Cattaneo F., Galimberti S. et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency // N. Engl. J. Med. 2009. Vol. 360. P. 448-458. DOI: 10.1056/NEJMoa0805817][Hacein-Bey-Abina S., Hauer J., Lim A. et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency // N. Engl. J. Med. 2010. Vol. 363. P. 355-364. DOI: 10.1056/NEJMoa1000164][Booth C., Gaspar H. B., Thrasher A. J. Gene therapy for primary immunodeficiency // Curr. Opin. Pediatr. 2011. Vol. 23. P. 659-666. DOI: 10.1097/MOP.0b013e32834cd67a][Frantz S. Engineered T-cell therapy shows efficacy in blood cancer // Nat. Biotechnol. 2011. Vol. 29. P. 853-855. DOI: 10.1038/nbt1011-853][Porter D., Levine B., Kalos M. et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia // N. Engl. J. Med. 2011. Vol. 365. P. 725-733. DOI: 10.1056/NEJMoa1103849][Grupp S. A., Kalos M. , D. Barrett et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia // N. Engl. J. Med. 2013. Vol. 368. P. 1509-1518. DOI: 10.1056/NEJMoa1215134][Five Years Later, First Pediatric Recipient of CAR T-Cell Therapy Remains Cancer-free. 2017. URL: https://www.chop.edu/news/five-years-later-first-pediatric-recipient-car-t-cell-therapy-remains-cancer-free (дата обращения: 10.05.2022).][Pennisi E. The CRISPR craze // Science. 2013. Vol. 341. P. 833-836. DOI: 10.1126/science.341.6148.833][Sander J. D., Sander J. D., Joung J. K. CRISPR-Cas systems for editing, regulating and targeting genomes // Nat. Biotechnol. 2014. Vol. 32, N 4. P. 347-355. DOI: 10.1038/nbt.2842][Gruber K. Europe gives gene therapy the green light // Lancet. 2012. Vol. 380, N 9855. Р. е10. DOI: 10.1016/S0140-6736(12)61992-8][Stroes E., Nieman M., Meulenberg J. et al.Intramuscular administration of AAV1-lipoprotein lipaseS447× lowers triglycerides in lipoprotein lipase-deficient patients // Arterioschler. Thromb. Vasc. Biol. 2013. Vol. 28. P. 2303-2304. DOI: 10.1161/ATVBAHA.108.175620.][Gaudet D., Stroes E. S., Méthot J. et al. Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis // Human Gene Ther. 2016. Vol. 27, N 11. P. 916-925. DOI: 10.1089/hum.2015.158][Червяков Ю. В., Староверов И. Н., Нерсесян Э. Г. и др. Терапевтический ангиогенез в лечении больных с хроническими облитерирующими заболеваниями артерий нижних конечностей, ближайшие и отдаленные результаты // Ангиология и сосудистая хирургия. 2012. Т. 18, № 3. С. 19-27.][Orchard Statement on Strimvelis®, a Gammaretroviral Vector-Based Gene Therapy for ADA-SCID. 2020. URL: https://ir.orchard-tx.com/node/7746/pdf (дата обращения: 25.05.2022).][Cyranoski D. CRISPR gene-editing tested in a person for the first time // Nature. 2016. Vol. 539, N 7630. Р. 479. DOI: 10.1038/nature.2016.20988][Ledford H. CRISPR treatment inserted directly into the body for first time // Nature. 2020. Vol. 579. P. 185. DOI: 10.1038/d41586-020-00655-8][Reardon S. First CRISPR clinical trial gets green light from US panel // Nature. 2016. DOI: 10.1038/nature.2016.20137][Lu Y., Zhou X., Xue J. et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer // Nat. Med. 2020. Vol. 26. P. 732-740. DOI: 10.1038/s41591-020-0840-5][Молчанова М. Клетки, которые спасают людей, и люди, которые преобразуют клетки. 2019. URL: https://podari-zhizn.ru/ru/publications/33467 (дата обращения: 12.03.2022).][Marchione M. AP exclusive: US scientists try 1st gene editing in the body. 2017. URL: https://apnews.com/4ae98919b52e43d8a8960e0e260feb0a/AP-Exclusive:-US-scientists-try-1st-gene-editing-in-the-body (дата обращения: 12.03.2022).][Chakradhar S. Treatments that made headlines in 2018 // Nat. Med. 2018. Vol. 24, N 12. P. 1785-1787. DOI: 10.1038/s41591-018-0292-3][Hu B., Zhong L., Weng Y. et al. Therapeutic siRNA: state of the art // Signal Transduct Target Ther. 2020. Vol. 19, N 5(1). P. 101. DOI: 10.1038/s41392-020-0207-x][Zhang M. M., Bahal R., Rasmussen T. P. et al. The growth of siRNA-based therapeutics: Updated clinical studies // Biochem. Pharmacol. 2021. Vol. 189. P. 114432. DOI: 10.1016/j.bcp.2021.114432][Komatsuno T. The First Gene Therapy Product in Japan Collategene® Intramuscular Injection // Drug Delivery System. 2019. Vol. 34. P. 305-308. DOI: 10.2745/dds.34.305][Highlights of prescribing information. 2019. URL: https://www.fda.gov/media/126109/download (дата обращения: 26.05.2022).][Ramamoorthy A., Karnes J. H., Finkel R. et al. Evolution of next generation therapeutics: past, present, and future of precision medicines // Clin. Transl. Sci. 2019. Vol. 12, N 6. P. 560-563. DOI: 10.1111/cts.12675][В НМИЦ онкологии им. Н. Н. Петрова началось клиническое исследование первого в России противоопухолевого препарата на основе онколитического вируса. 2022. URL: https://www.niioncologii.ru/news/v_nmits_onkologii_im_n_n_petrova_nachalos_klinicheskoe_issledovanie_pervogo_v_rossii_protivoopukhole (дата обращения: 27.05.2022).][ФМБА работает над аналогом самого дорогого препарата от СМА. 2022. URL: https://ria.ru/20220525/zolgensma-1790612994.html (дата обращения: 26.05.2022).][Пестрикова А. А., Холопова Е. Н. Формирование принципов правового регулирования редактирования генома зародышевой линии человека // Правовое государство: теория и практика. 2020. Т. 62. С. 144-156. DOI: 10.33184/pravgos-2020.4.31][Coller B. S. Ethics of human genome editing // Annu. Rev. Med. 2019. Vol. 70. P. 289-305. DOI: 10.1146/annurev-med-112717-094629][Vassena R., Heindryckx B., Peco R. et al. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells // Hum. Reprod. Update. 2016. Vol. 22, N 4. P. 411-419. DOI: 10.1093/humupd/dmw005]